Latest Ikarovec News
Oct 5, 2020
Ikarovec one of Scrip’s ‘10 To Watch’ at BIO-Europe Digital, October 26-29 Company presentation & partnering opportunities now available online Ikarovec , which is developing novel gene therapies to treat major ophthalmic indications, is pleased to announce that it has been named one of Scrip’s ’10 To Watch’ companies at Bio-Europe Digital. This is a nomination for emerging companies displaying promise in drug discovery and development. BIO-Europe 2020 is being delivered digitally. The opportunity to view Ikarovec’s presentation and book a partnering meeting with the Executive Chairman, Dr Robert Haigh, is available here . Dr Haigh’s presentation discusses the potential of the company’s approach in devastating eye diseases, and its progress since inception. Ikarovec launched earlier this year with £2.5m of seed funding from UKI2S with co-investment from LifeArc and Parkwalk. Primary use of funds is to take the company’s lead programme, a multicistronic gene therapy for diabetic macular edema, to IND-enabling studies. It was recently awarded a £458,740 Innovate UK grant for one of its earlier stage programmes in wet age-related macular degeneration. Ikarovec has recently taken laboratory and office space in the Innovation Centre at Norwich Research Park, with access to shared scientific facilities. The location also brings proximity to Norwich Medical School and a clinical trials unit which will be valuable as the company develops. –ENDS— Robert Haigh, Executive Chairman
Ikarovec Frequently Asked Questions (FAQ)
When was Ikarovec founded?
Ikarovec was founded in 2019.
Where is Ikarovec's headquarters?
Ikarovec's headquarters is located at Cambridge.
What is Ikarovec's latest funding round?
Ikarovec's latest funding round is Seed VC.
How much did Ikarovec raise?
Ikarovec raised a total of $3.25M.
Who are the investors of Ikarovec?
Investors of Ikarovec include UK Innovation & Science Seed Fund, Parkwalk Advisors and LifeArc.